1. MK-8628 promotes T lymphocyte cell cycle arrest.
MK-8628 promotes T lymphocyte cell cycle arrest. (A and B) Flow cytometry contour plots of cyclin B1 expression in anti-CD3/CD28 mAb–stimulated CD4+ and CD8+ T lymphocytes treated with 0.19 μM MK-8628 or untreated controls after 48 h. (C and D) Dose response of B1 cell cyclin expression in CD4+ and CD8+ T lymphocytes as shown in (A) and (B). (E and F) Flow cytometry contour plots of cyclin D3 expression in anti-CD3/CD28 mAb–stimulated CD4+ and CD8+ T lymphocytes treated with 0.19 μM MK-8628 or untreated controls after 48 h. (G and H) Dose response of D3 cell cyclin expression in CD4+ and CD8+ T lymphocytes as shown in (E) and (F). (I and J) Flow cytometry contour plots of Click-iT Plus EdU AF488 fluorescence and FxCycle Far Red fluorescence depicting gap 1, synthesis, and mitosis cell cycle phases (G1, S, and M) in anti-CD3/CD28 mAb–stimulated CD4+ and CD8+ T lymphocytes treated with 0.19 μM MK-8628 or untreated controls after 48 h. (K and L) Frequency of CD4+ and CD8+ T lymphocytes in S phase as shown in (I) and (J). Data are from one experimental representative of at least three independent experiments and represent triplicate (C, D, G, and H) or duplicate (K and L) wells; small horizontal red lines indicate the mean. **p < 0.01, ***p < 0.001, ****p < , one-way ANOVA with posttest analysis.
Peter Georgiev et al. ImmunoHorizons 2019;3:
Copyright © 2019 The Authors